CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Heart failure with preserved ejection fraction: from mechanisms to therapies Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators - The RAID Trial Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week Ejection Fraction Pros and Cons: JACC State-of-the-Art Review Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction sST2 Predicts Outcome in Chronic Heart Failure Beyond NT−proBNP and High-Sensitivity Troponin T

Editorial17 Nov 201

JOURNAL:Circulation. Article Link

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF

Martinez FA, Serenelli M, Nicolau JC et al. Keywords: dapagliflozin; HFrEF; efficacy; safety

FULL TEXT PDF